Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1991 1
1993 3
1994 1
1995 1
1996 2
1997 2
1998 1
1999 2
2000 2
2001 6
2002 5
2003 4
2004 6
2005 8
2006 11
2007 6
2008 11
2009 9
2010 9
2011 8
2012 10
2013 14
2014 7
2015 8
2016 11
2017 18
2018 12
2019 13
2020 8
2021 17
2022 7
Text availability
Article attribute
Article type
Publication date

Search Results

198 results
Results by year
Filters applied: . Clear all
Page 1
A review of Formulations of Commercially Available Antibodies.
Strickley RG, Lambert WJ. Strickley RG, et al. J Pharm Sci. 2021 Jul;110(7):2590-2608.e56. doi: 10.1016/j.xphs.2021.03.017. Epub 2021 Mar 28. J Pharm Sci. 2021. PMID: 33789155 Review.
The pH range is 4.8-8.0 and the buffers or pH-modifying agents include histidine, citrate, succinate, acetate, phosphate, glutamate, adipic acid, aspartic acid, lactic acid, tromethamine, and 2-(N-morpholino)-ethanesulfonic acid. The surfactants include mostly polysorbate …
The pH range is 4.8-8.0 and the buffers or pH-modifying agents include histidine, citrate, succinate, acetate, phosphate, glutamate, adipic …
Therapeutic Oligonucleotides: State of the Art.
Smith CIE, Zain R. Smith CIE, et al. Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:605-630. doi: 10.1146/annurev-pharmtox-010818-021050. Epub 2018 Oct 9. Annu Rev Pharmacol Toxicol. 2019. PMID: 30285540 Review.
Locked nucleic acid and constrained ethyl, a related variant, are bridged forms where the 2'-oxygen connects to the 4'-carbon in the sugar. Phosphorodiamidate morpholino oligomers, carrying a modified heterocyclic backbone ring, have also been commercialized. ...
Locked nucleic acid and constrained ethyl, a related variant, are bridged forms where the 2'-oxygen connects to the 4'-carbon in the sugar. …
Viltolarsen for the treatment of Duchenne muscular dystrophy.
Roshmi RR, Yokota T. Roshmi RR, et al. Drugs Today (Barc). 2019 Oct;55(10):627-639. doi: 10.1358/dot.2019.55.10.3045038. Drugs Today (Barc). 2019. PMID: 31720560 Review.
It is caused by a lack of dystrophin protein due to mutations in the DMD gene, which can disrupt the reading frame of the dystrophin primary transcript. Antisense oligonucleotides such as phosphorodiamidate morpholino oligomers (PMOs) can induce exon skipping during pre-mR …
It is caused by a lack of dystrophin protein due to mutations in the DMD gene, which can disrupt the reading frame of the dystrophin primary …
Antisense oligonucleotides: absorption, distribution, metabolism, and excretion.
Shadid M, Badawi M, Abulrob A. Shadid M, et al. Expert Opin Drug Metab Toxicol. 2021 Nov;17(11):1281-1292. doi: 10.1080/17425255.2021.1992382. Epub 2021 Oct 22. Expert Opin Drug Metab Toxicol. 2021. PMID: 34643122 Review.
AREAS COVERED: This review highlights the two major backbones that are currently used to build the most advanced ASO platforms - the phosphorodiamidate morpholino oligomers (PMOs) and the phosphorothioates (PSs). The absorption, distribution, metabolism, and excretion (ADM …
AREAS COVERED: This review highlights the two major backbones that are currently used to build the most advanced ASO platforms - the phospho …
Golodirsen: First Approval.
Heo YA. Heo YA. Drugs. 2020 Feb;80(3):329-333. doi: 10.1007/s40265-020-01267-2. Drugs. 2020. PMID: 32026421 Review.
Golodirsen (Vyondys 53()), an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO) subclass designed to induce exon 53 skipping, has been developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD). ...
Golodirsen (Vyondys 53()), an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO) subclass designed to induc …
Casimersen: First Approval.
Shirley M. Shirley M. Drugs. 2021 May;81(7):875-879. doi: 10.1007/s40265-021-01512-2. Epub 2021 Apr 16. Drugs. 2021. PMID: 33861387 Review.
Casimersen (Amondys 45) is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a mutation in the DMD gene that is amenable to exon …
Casimersen (Amondys 45) is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass developed by Sarepta T …
Eteplirsen in the treatment of Duchenne muscular dystrophy.
Lim KR, Maruyama R, Yokota T. Lim KR, et al. Drug Des Devel Ther. 2017 Feb 28;11:533-545. doi: 10.2147/DDDT.S97635. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28280301 Free PMC article. Review.
Timolol.
[No authors listed] [No authors listed] 2021 Oct 18. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. 2021 Oct 18. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. PMID: 30000225 Free Books & Documents. Review.
198 results